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Abstract
Introduction Patients with rheumatoid arthritis (RA) have an
increased frequency of osteoporosis, mainly because of
increased bone resorption. Reduction of disease activity is
suggested to reduce bone remodelling. It might also be possible
that prednisolone treatment could cause this effect because
prednisolone has been shown to arrest the development of joint
destruction in early RA. Therefore, we examined the effects of
low-dose prednisolone on serum concentrations of bone
remodelling markers and insulin-like growth factor-1 (IGF-1) in
RA patients in relation to bone mineral density.
Methods One hundred and fifty patients, 67% women, with
early RA, mean disease duration of six months (95% confidence
interval (CI) = three to eight months), who had participated in
the BARFOT (Better Anti-Rheumatic FarmacOTherapy) low-
dose prednisolone study were included. They had been
randomised to either the P-group, who were treated with 7.5 mg
prednisolone daily (n = 70, mean age = 51 years, 95% CI 48 to
54 years), or the NoP-group, who received no prednisolone (n =
80, mean age 58 years, 95% CI 56 to 61 years), when they
started their first disease-modifying anti-rheumatic drug
(DMARD). Serum samples were analysed at baseline, 3 and 12
months for procollagen type I N-terminal propeptide (P1NP), a
marker of bone formation, and the C-telopeptide crosslaps of
type I collagen (CTX-1) and C-terminal telopeptide of type I
collagen (1CTP), markers of bone degradation. IGF-1 was
analysed at baseline and after 12 months. Bone mineral density
at the lumbar spine and femoral neck was assessed by dual-
energy X-ray absorptiometry at baseline and after 24 months.
Results Levels of P1NP decreased rapidly in the P-group (p <
0.001). Levels of CTX-1 and 1CTP decreased in both treatment
groups, but significantly more in the P-group (differences
between groups p < 0.019 and p < 0.001, respectively). IGF-1
increased in the P-group (p < 0.001) but remained stable in the
NoP-group. Bone mineral density decreased in the spine in both
groups, significantly more in postmenopausal women from the
P-group. Femur bone mineral density only decreased in the
NoP-group.
Conclusions Low-dose prednisolone in early RA counteracts
the negative impact of rheumatoid inflammation on bone tissue
in the hip, a juxta-articular localisation. Thus bone mineral density
was preserved in the femur in the P-group and 1CTP decreased
rapidly. However, the systemic inflammatory consequences on
bone could not be prevented in the lumbar spine, especially not
in postmenopausal women, probably because of the combined
effect of suppression of bone synthesis by prednisolone and the
postmenopausal status.
BARFOT: Better Anti-Rheumatic FarmacOTherapy; BMI: body mass index; BMD: bone mineral density; CI: confidence interval; CRP: C-reactive pro-
tein; 1CTP: C-terminal telopeptide of type I collagen; CTX-1: C-telopeptide crosslaps of type I collagen; DAS28: disease activity score of 28 joints; 
DMARD: disease-modifying anti-rheumatic drug; DXA: dual-energy X-ray absorptiometry; ESR: erythrocyte sedimentation rate; HAQ: health Assess-
ment Questionnaire; IGF-1: insulin-like growth factor-1; IGFSD: IGF standard deviations; IL: interleukin; IQR: inter quartile range; MMPs: matrix- met-
alloproteases; NoP-group: no prednisolone treated group; P-group: prednisolone treated group; P1NP: procollagen type I N-terminal propeptide; RA: 
rheumatoid arthritis.Arthritis Research & Therapy    Vol 10 No 6    Engvall et al.
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Introduction
Rheumatoid arthritis (RA) is associated with an increased risk
of osteoporosis followed by an increased fracture rate [1-3].
This has been attributed to inflammatory activity and
decreased physical activity but also to treatment with gluco-
corticoids and muscle weakness, which increases the likeli-
hood of falls [1].
Bone is continuously being remodelled in a process by which
osteoclasts resorb bone tissue and osteoblasts produce new
bone matrix that is subsequently mineralised. Bone loss
occurs when the balance shifts toward excess resorption [4].
In RA, the main reason for bone loss is increased bone resorp-
tion, secondary to cytokine-activated osteoclasts, although
data on bone formation are conflicting [1].
It has been suggested that treatment which reduces inflamma-
tory activity in RA may prevent bone loss [5]. Therefore, short-
term treatment with infliximab has beneficial effects on markers
of bone metabolism in patients with active RA [6].
In recent years, glucocorticoid treatment in low doses has
been re-evaluated because of its ability to reduce radiographic
damage in early RA [7-9]. The side effects of glucocorticoids
in RA are still debated, especially the effects on skeletal tissue
[10-13].
Glucocorticoid treatment suppresses bone formation by its
effects on the osteoblasts. It also changes the micro-architec-
ture and hence the quality of bone, which increases the frac-
ture risk independent of bone mineral density (BMD) [14].
However, in low doses (≤ 7.5 mg) it has been suggested that
this suppressive effect on bone synthesis may be compen-
sated by the ability of glucocorticoids to hamper disease activ-
ity and thus the inflammatory mediated increase in bone
resorption [15].
Fracture risk and osteoporosis are strongly related to BMD,
which is therefore widely estimated by dual-energy X-ray
absorptiometry (DXA). As a complement to the static meas-
urement of BMD, analyses of biochemical markers of bone
turnover are used, because these are useful in predicting
future changes in bone mass [16,17]. Also, high bone turno-
ver, detected by biochemical bone markers, might be related
to deleterious bone architecture, not detected by DXA [4].
However, the role of assays of bone turnover markers for
detection of the effects of glucocorticoids on bone has not
been established.
Several markers have been described to measure bone
metabolism but it has been difficult to differ between different
mechanisms of bone resorption. The type I collagen telopep-
tide fragments, C-telopeptide crosslaps of type I collagen
(CTX-1) and C-terminal telopeptide of type I collagen (1CTP),
are currently considered as the most sensitive markers of bone
resorption and are released from bone type I collagen by dif-
ferent enzymatic pathways. CTX-1 is generated by cathepsin
K, which is the key osteoclastic enzyme for systemic bone
resorption. In contrast, 1CTP is generated by matrix-metallo-
proteases (MMPs) whose activity plays an important role in
collagen degradation associated with RA [18,19].
Insulin-like growth hormone (IGF-1) is considered to be the
most important skeletal growth factor and it stimulates synthe-
sis of collagen type I, increases matrix apposition rates and
inhibits collagen degradation, effects that are important for
bone synthesis and maintenance of bone matrix [20]. Gluco-
corticoids inhibit IGF-1 activity and it is postulated that a
reduction in local IGF-1 synthesis is responsible for the inhibi-
tion of bone formation caused by steroids [20]. There are lim-
ited data about IGF-1 and its association with BMD in RA [21].
The present study on patients with early RA was performed to
investigate: the effects of glucocorticoid treatment on bone
remodelling markers in relation to BMD; to find possible pre-
dictors of changes in BMD; and to study the association of
IGF-1 in relation to bone markers and BMD.
Materials and methods
Patients
A total of 150 patients (67% women) of the 250 patients with
early RA who participated in the BARFOT (Better Anti-Rheu-
matic FarmacOTherapy) low-dose prednisolone study (a
Swedish multi-centre study designed to investigate clinical
and therapeutic aspects of early RA) were included in this
study [22] between 1995 and 1999. Details of the study pro-
tocol have been previously described [9]. Briefly, these
patients had a diagnosis of RA according to the American Col-
lege of Rheumatology criteria [23], were between 18 and 80
years of age, had a disease duration of less than one year and
had active disease defined as a Disease Activity Score of 28
joints (DAS28) of more than 3.0. Exclusion criteria were earlier
treatment with glucocorticoids and for patients younger than
65 years a T-score lower than -2.5 SD on DXA or for patients
65 years and older a Z-score of less than -1.0 SD. The patients
were randomised to treatment with 7.5 mg prednisolone daily
(P-group) or no prednisolone (NoP-group) when they started
their first disease-modifying anti-rheumatic drug (DMARD),
which was chosen by the treating physicians, in accordance
with the recommended treatment strategy in Sweden at the
time of the study. According to the protocol all patients should
be prescribed 1 g calcium daily. Treatment with non-steroidal
anti-inflammatory drugs was permitted and intra-articular ster-
oid treatment was also allowed. The patients were followed
prospectively for two years.
To be included in this evaluation study, patients should had
DXA measurements and X-rays of their hands and feet per-
formed at baseline and at two years follow-up. The finalAvailable online http://arthritis-research.com/content/10/6/R128
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numbers of patients were 70 patients in the P-group and 80
patients in the NoP-group.
The study was approved by the ethics committee at Karolinska
University Hospital (KI 153-95), Lund University Hospital (LU
154-95), Sahlgrenska University Hospital in Gothenburg (Gbg
M45–95) and Linköping University Hospital (Li 123-95), and
was performed according to the Helsinki declaration. All
patients signed informed consents.
Clinical assessments
Disease activity was assessed with C-reactive protein (CRP)
and with DAS28, calculated from the number of swollen and
tender joints, the erythrocyte sedimentation rate (ESR) and the
patient's global assessment of health measured on a visual
analogue scale (1 to 100 mm) [23]. Active disease was
defined as DAS28 more than 3.0. Functional status was meas-
ured using the Swedish version of the Stanford Health
Assessment Questionnaire (HAQ) [24]. The HAQ score
ranges from 0 to 3, where a higher score indicates a higher
degree of disability. Body mass index (BMI) was calculated by
dividing body weight by the square of height in metres (kg/m2).
Dual-energy X-ray absorptiometry
Bone mineral density (BMD) was measured at each centre by
DXA with a densitometer (GE-Lunar Progidy, Madison, Massa-
chusetts, USA) at the lumbar spine (L2 to L4) with anterior-
posterior view and at the left hip (femoral neck) [25]. BMD was
expressed in grams of bone mineral per square centimetre (g/
cm2), as the number of standard deviations (SD) from the
mean of healthy age- and sex-matched people, the Z-score,
and as the number of SD from the mean of healthy, young sex-
matched people, the T-score. The values were obtained from
Lunars combined European/US reference population [26].
Markers of bone turnover
Serum samples were obtained between 9 am and 3 pm and
stored at -70°C until assay. For most patients the samples
were taken at the same time of the day. All samples from the
individual patient were analysed simultaneously to minimise
inter-assay variations. The bone markers were analysed at the
study centre for laboratory medicine, Karolinska university lab-
oratory, Stockholm, Sweden.
Procollagen type I N-terminal propeptide (P1NP) was used as
a marker of bone formation, and CTX-1 and 1CTP as markers
of bone degradation. P1NP was determined by Elecsys 1010/
2010 total P1NP serum kit (Roche Diagnostics, Mannheim,
Germany), which employs the electrochemiluminescence
immunoassay (ECLIA) technique. The measuring range is 5 to
1200 μg/L. The median and the 5th and 95th percentiles in
premenopausal women are 27.8, 15.13 and 58.59, respec-
tively. For postmenopausal women the corresponding figures
are 37.09, 16.27 and 73.87, respectively. The intra-assay
coefficients of variation (CV) is 2.3% and total precision CV
2.9%.
CTX-1 was determined by Elecsys 1010/2010 β-CrossLaps/
serum kit (Roche Diagnostics, Mannheim, Germany), which
also employs the ECLIA technique. The sensitivity of the assay
is 0.01 ng/ml. The mean (SD) and mean +2SD figures are: for
premenopausal women 0.299 (0.137) ng/mL and 0.573 ng/
mL; for postmenopausal women 0.556 (0.226) ng/mL and
1.008 ng/mL; for men 30 to 50 years 0.300 (0.142) ng/mL
and 0.584 ng/mL; men 50 to 70 years 0.304 (0.200) ng/mL
and 0.704 ng/mL; and for men older than 70 years 0.394
(0.230) ng/mL and 0.854 ng/mL. The intra-individual CV is
17.9%. The intra-assay CV is 2.4% and total precision CV is
3.1%.
1CTP was determined by Multigamma radioimmunoassay kit
(Orion Diagnostica, Espoo, Finland). The sensitivity of the
assay is 0.5 μg/L. The reference interval is 1.8 to 5.0 μg/L. The
intra- and interassay CV is 5.3% and 4.25%, respectively.
Cytokine
Interleukin (IL) 6 was analysed at the study centre for labora-
tory medicine, Karolinska university laboratory, Stockholm,
Sweden, and was determined in serum by the commercial kits
Quantikine HS human IL-6 immunoassay (R& D Systems, Inc.,
Minneapolis, MN, US), which is a solid-phase ELISA that
employs the quantitative sandwich enzyme immunoassay
technique. The sensitivity of the assay is 0.039 pg/ml. The
mean and range of IL-6 are 1.77 pg/ml and 0.447 to 9.96 pg/
ml. The intra- and interassays CV are 7.4% and 7.8%,
respectively.
Anabolic factors
IGF-1 was analysed at the Centre for Diabetes Research,
Department of Molecular Medicine and Surgery, Karolinska
Institutet, Stockholm, Sweden. IGF-1 in serum was deter-
mined by radioimmunoassay (RIA) after separation of IGFs
from its regulating binding proteins (IGFBPs) by acid ethanol
extraction and cryoprecipitation. To minimise interference of
remaining IGFBPs, des (1–3) IGF-1 was used as radioligand
[27]. The intra- and interassay CV are 4% and 11%. As serum
levels of IGF-1 are age dependent, decreasing with age, IGF-
1 values were also expressed as SD scores calculated from
the regression of the values of 247 healthy adult subjects [28].
Statistical analysis
STATISTICA, release 7 (Stat Soft Scandinavia AB, Tulsa, OK,
USA) was used for statistical analysis. Data were presented as
mean (confidence interval (CI)) or median (interquartile range)
depending on its distribution. Comparison between groups
was performed with Mann-Whitney U test because many vari-
ables were not normally distributed. When comparing two
binary variables Fisher's exact test or chi squared test were
performed. Correlation analyses were performed withArthritis Research & Therapy    Vol 10 No 6    Engvall et al.
Page 4 of 12
(page number not for citation purposes)
Spearman Rank Order Correlations. We used a Wilcoxon
matched pairs test to compare changes between different
time-points. Multivariate analyses were performed with multi-
ple linear regression. Changes in BMD at the lumbar spine
with respect to the femoral neck were chosen as dependent
variables. We used stepwise forward regression analyses to
find the most robust model. Variables known to be important
for osteoporosis were included in the final models: age, gen-
der, smoking and menopausal status.
Results
Demographic and clinical variables at baseline are presented
in Table 1. The prednisolone-treated group (P-group) was sig-
nificantly younger and had fewer postmenopausal women
compared with the no prednisolone group (NoP-group). Dis-
ease activity, Z-scores and bone remodelling markers were
similar at baseline. The median levels of all the bone markers
were in the normal range compared with the reference values.
Concomitant treatment
DMARDs were given to all patients at baseline. In the P-group,
49% started with methotrexate and 39% with sulfasalazine.
The corresponding percentages for the NoP-group were 44%
and 45%, respectively. At the two-year visit, several patients in
each group had switched from treatment with SSZ to meth-
otrexate in most cases but also to other or no DMARDs, and
9% in the P-group and 15% in the NoP-group were no longer
receiving DMARDs. One patient was treated with a biological
agent from year one to two. None of the patients were treated
with bisphosphonates before inclusion in the study or during
the two years of the study. At baseline 38% of the postmeno-
pausal women were treated with hormone replacement ther-
apy (41% in the P-group and 36% in the NoP-group with no
significant difference between the groups).
Table 1
Baseline characteristics of the 150 patients treated with or without prednisolone
Prednisolone n = 70 No prednisolone n = 80 p level
Age, years 51.3(48.2 to 54.4) 58.4 (55.6 to 61.2) 0.001
Disease duration, months 6.3 (5.5 to 7.1) 5.7 (5.1 to 6.4) 0.27
Women, % 69 65 0.64
Menopause, % 50 69 0.05
Menopause age, years* 50(48 to 51) 50(47 to 52) 0.97
Current or previous smoker, % 67 56 0.13
BMI*, kg/m2 24.3 (22.5 to 27.0) 25.6 (23.5 to 29.1) 0.07
RF positivity, % 66 55 0.25
Erosive disease, % 53 56 0.68
DAS28 5.2 (4.9 to 5.5) 5.5 (5.3 to 5.7) 0.12
ESR 39(33 to 44) 39(33 to 45) 0.96
CRP* 22(10 to 45) 21(10 to 58) 0.50
IL-6* 9.9(8.0 to 19.4) 11.7(9.2 to 27.6) 0.44
HAQ 1.0 (0.9 to 1.2) 1.0 (0.8 to 1.1) 0.52
Z-score, L2–L4* 0.36 (-0.24 to 0.88) 0.50 (-0.36 to 1.37) 0.29
Z-score neck* 0.01 (-0.56 to 1.00) -0.02 (-0.52 to 0.69) 0.87
P1NP*, μg/L 38.3 (28.0 to 51.8) 40.8 (28.8 to 57.0) 0.50
CTX-1*, ng/mL 0.26 (0.20 to 0.35) 0.33 (0.19 to 0.42) 0.17
1CTP* μg/L 4.5 (3.5 to 5.7) 4.2 (3.4 to 6.4) 0.62
IGF-1, μg/L* 173 (135 to 202) 210 (185 to 250) 0.34
IGFSD 0.15 (-0.06 to 0.6) 1.0 (0.4 to 1.6) 0.42
Data presented as mean (95% confidence interval) or median (interquartile range).
* depending on its distribution.
BMI = body mass index; CRP = C-reactive protein; 1CTP = C-terminal propeptide of type I collagen; CTX-1 = C-terminal telopeptide of type I 
collagen; DAS = disease activity score; ESR = erythrocyte sedimentation rate; HAQ = health assessment questionnaire; IGF-1 = insulin-like 
growth factor 1; IGFSD = IGF-1, standard deviation-scores; IL-6 = interleukin-6; P1NP = Procollagen type I N-terminal propeptide; RF = 
rheumatoid factor. Bold p values are statistically significant.Available online http://arthritis-research.com/content/10/6/R128
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Disease activity
At baseline all patients had high disease activity measured by
DAS28, ESR, CRP and IL-6 but, as expected, these measures
decreased significantly in both the P and NoP groups after
three months (p < 0.001 for DAS28, ESR and CRP in both
treatment groups; IL-6 not measured) and after 12 months (for
the P-group p < 0.001 for DAS28, ESR and CRP and p =
0.015 for IL-6, for the NoP-group p < 0.001 for DAS28, ESR
and CRP and p = 0.13 for IL-6. The difference between the
treatment groups was in favour of the P-group considering
ESR reduction at 3 and 12 months (p = 0.001 and p = 0.019,
respectively) and a trend also for IL-6 at 12 months (p =
0.051).
Bone mineral density
Table 2 presents the results of DXA measurements at baseline
and the changes after two years. In the P-group, BMD at the
lumbar spine had decreased significantly at two years (-2.8%,
p < 0.001), although BMD had remained stable in the femoral
neck (-0.75%, p = 0.20). In the NoP-group BMD had
decreased significantly both at the lumbar spine (-1.1%, p =
0.034) and femoral neck (-1.9%, p < 0.001). Only the reduc-
tion in Z-score in the lumbar spine was significantly different
between the treatment groups.
As age and percentage of postmenopausal women differed
between the treatment groups, we also performed the statisti-
cal analyses with women around menopause excluded (age
between 47 and 52 years, 10 women in the P-group, 6 women
in the NoP-group). We then found no significant differences
between the treatment groups in changes in BMD or Z-score
(baseline 24 months), either in the lumbar spine or femoral
neck, data not shown.
Looking at the groups with those women around menopausal
age excluded, there were significant differences when looking
at changes in BMD at the lumbar spine between the women in
the P-group and those in the NoP-group (median -3.8% (-5.9
to -0.3%) and median -0.3% (-2.4 to 2.3%), respectively (p =
0.004)). The same was found for Z-scores at the lumbar spine
median -0.30 (-0.60 to -0.10) and median 0.00 (-0.29 to 0.29),
respectively, p = 0.007). At the femoral neck there was no sig-
nificant differences in changes in BMD or Z-score for women,
with those around menopausal age excluded (p = 0.63 and
0.92, respectively). No difference between the treatment
groups was shown for premenopausal women or for men
either in the lumbar spine or femoral neck (data not shown).
During the two-year study period, there were five new frac-
tures in the P-group (all vertebral, and also a hip fracture for
one patient) and six new fractures in the NoP-group (four ver-
tebral, one fracture of the humerus and one fracture of the
ankle joint) with no significant difference between the treat-
ment groups.
Bone turnover markers
At baseline, the median serum levels of all the bone markers
were within the normal reference ranges. However, 11% of the
women had elevated P1NP (reference values for men not
available), 8% of the patients had elevated CTX-1 and 38%
had elevated 1CTP.
Table 2
Dual X-ray absorptiometry measurements at baseline and the changes after two years, separated for the two treatment groups
P-group NoP-group P vs NoP
Baseline Change baseline to 2 
years
p value 
change
Baseline Change baseline to 
2 years
p value 
change
p value 
change
BMD, g/cm2 L2 
to L4
1.180 (1.070 to 
1.263)
-0.032 (-0.063 to 
0.010) = -2.8 (-5.9 to 
1.0) %
<0.001 1.119 (1.063 to 
1.227)
-0.013 (-0.054 to 
0.025) = -1.1(-4.8 to 
2.0) %
0.034 0.08
Z-score L2 to 
L4
0.36 (-0.24 to 0.88) -0.30 (-0.60 to -0.01) <0.001 0.50 (-0.36 to 
1.37)
-0.10 (-0.51 to 0.24) 0.029 0.043
T-score L2 to 
L4
-0.17 (-1.03 to 
0.56)
-0.30 (-0.51 to 0.06) <0.001 -0.37 (-1.16 to 
0.42)
-0.10 (-0.45 to 0.20) 0.035 0.07
BMD, g/cm2 
neck
0.963 (0.837 to 
1.047)
-0.008 (-0.045 to 
0.021) = -0.75 (-4.9 
to 2.2) %
0.20 0.903 (0.813 to 
0.981)
-0.014 (-0.056 to 
0.006) = -1.9 (-6.5 
to 0.6) %
<0.001 0.16
Z-score neck 0.01 (-0.56 to 1.00) -0.05 (-0.32 to 0.21) 0.43 -0.02 (-0.52 to 
0.69)
-0.10 (-0.46 to 0.11) 0.007 0.27
T-score neck -0.50 (-1.66 to 
0.30)
-0.03 (-0.39 to 0.18) 0.24 -0.84 (-1.58- to 
0.22)
-0.13 (-0.46 to 0.05) <0.001 0.12
Data is presented as median (interquartile range). Changes between baseline and two years are expressed as absolute difference for Z- scores and 
T-scores and for bone mineral density (BMD) also in percent. P = prednisolone-treated group, No-P = No prednisolone treated group. Bold p 
values are statistically significant.Arthritis Research & Therapy    Vol 10 No 6    Engvall et al.
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In the P-group, the marker for bone synthesis decreased rap-
idly during the first three months and more slowly thereafter
(Figure 1), whereas the bone resorption markers decreased
during the whole 12-month period (Figures 2 and 3).
In the NoP-group, the level of P1NP remained stable for the
total period (Figure 1). CTX-1 remained stable for the first
three months but decreased thereafter (Figure 2). 1CTP first
increased which was then followed by a decrease for the total
period (Figure 3).
When comparing the treatment groups, there were significant
differences concerning the changes for all the bone markers.
The decrease in bone formation occurred only in the P-group
and furthermore the decreases in the bone resorption markers
were significantly more pronounced and occurred earlier in the
P-group (Figures 1, 2 and 3).
Correlations between bone markers and bone mineral 
density
At baseline there were no significant correlations between the
levels of bone markers and baseline BMD at either skeletal
site.
Results of the univariate analyses are shown in Table 3. A
decreased bone turnover was associated with less loss of
bone, which affected the treatment groups differently. In the P-
group, mainly reduced levels of P1NP and 1CTP correlated
with changes in BMD at both skeletal sites. In contrast, in the
NoP-group, reduced levels of all the bone markers correlated
with changes in BMD at the lumbar spine, whereas only
reduced 1CTP correlated with changes in BMD at the femoral
neck.
Correlations between inflammatory activity and bone 
mineral density
Results of the univariate analyses are shown in Table 3.
Decrease of inflammation correlated in the P-group mainly
with less bone loss in the femoral neck, whereas for the NoP-
group it was correlated with less bone loss both in the spine
and femoral neck.
Correlations between inflammatory activity and bone 
markers
Including all patients, clinical and biochemical inflammatory
markers correlated positively with bone resorption markers at
Figure 1
Change in procollagen type I N-terminal propeptide (P1NP) median val- ues (IQR) at 0, 3 and 12 months for both treatment groups Change in procollagen type I N-terminal propeptide (P1NP) 
median values (IQR) at 0, 3 and 12 months for both treatment 
groups. P1NP is a marker of bone formation. The difference between 
the treatment groups was significant both at 3 months (p < 0.001) and 
12 months, (p < 0.001). 1 = baseline, 2 = 3 months, 3 = 12 months.
Figure 2
Change in C-terminal telopeptide cross-laps (CTX-1) median values  (IQR) at 0, 3 and 12 months for both treatment groups Change in C-terminal telopeptide cross-laps (CTX-1) median val-
ues (IQR) at 0, 3 and 12 months for both treatment groups. CTX-1 
is a marker of bone resorption. The difference between the treatment 
groups was significant both at 3 months (p = 0.005) and 12 months (p 
= 0.019). 1 = baseline, 2 = 3 months, 3 = 12 months.
Figure 3
Change in C-terminal telopeptide of type I collagen (1CTP) median val- ues (IQR) at 0, 3 and 12 months for both treatment groups Change in C-terminal telopeptide of type I collagen (1CTP) median 
values (IQR) at 0, 3 and 12 months for both treatment groups. 1-
CTP is a marker of bone resorption. The difference between the two 
treatment groups was significant, both at 3 months (p < 0.00) and 12 
months (p < 0.001). 1 = baseline, 2 = 3 months, 3 = 12 months.Available online http://arthritis-research.com/content/10/6/R128
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baseline. The highest correlations were found between 1CTP
and CRP (r = 0.48, p < 0.001) and IL-6 (r = 0.34, p < 0.001).
For the P-group reduction of CRP from 0 to 3 months corre-
lated significantly with reduction of CTX-1 during the same
time (r = 0.27, p = 0.042), as well as with reduction of 1CTP
(r = 0.35, p = 0.007). Reduction in CRP from 0 to 12 months
correlated with reduction in 1CTP 0 to 12 months (r = 0.40, p
= 0.002), but not significantly with a change in CTX-1 at the
same time point.
In the NoP-group reduction of CRP from 0 to 3 months corre-
lated with increase in P1NP from 0 to 3 months (r = -0.39, p
= 0.001), as well as with increase in 1CTP (r = -0.36, p =
0.003). Reduction of CRP and IL-6 from 0 to 12 months cor-
related with reduction in CTX-1 from 0 to 12 months (r = 0.35,
p = 0.005 and r = 0.34, p = 0.005, respectively), but not with
change in 1CTP.
Thus, reduced inflammation 0 to 3 months was associated
with different patterns of the bone markers in the two treat-
ment groups. Reduced inflammation at 0 to 12 months corre-
lated with reduced levels of 1CTP in the P-group and with
reduced levels of CTX-1 in the NoP-group.
Table 3
Correlations between bone markers, inflammatory variables and IGFSD at different time-points and changes in bone mineral 
density during 24 months for the two treatment groups
Prednisolone group No prednisolone group
Δ BMD L2 toL4, 0 to 24 
months
Δ BMD neck, 0 to 24 
months
Δ BMD L2 to L4, 0 to 24 
months
Δ BMD neck, 0 to 24 
months
Age ns Ns ns ns
BMI, baseline ns r = 0.26, p = 0.031 ns r = 0.39, p < 0.001
P1NP, baseline ns Ns r = -0.36, p = 0.002 ns
P1NP, 12 months r = -0.24, p = 0.057 r = -0.30, p = 0.018 r = -0.37, p = 0.002 ns
ΔP1NP, 0 to 12 months ns ns ns ns
CTX-1, baseline ns ns ns ns
CTX-1, 12 months ns ns r = -0.36, p = 0.002 ns
ΔCTX-1, 0 to12 months ns r = -0.26, p = 0.045 ns ns
1CTP, baseline ns ns ns r = -0.27, p = 0.020
1CTP, 12 months ns r = -0.24, p = 0.059 r = -0.28, p = 0.017 r = -0.22, p = 0.072
Δ1CTP, 0 to 12 months r = -0.29, p = 0.026 r = -0.33, p = 0.010 ns Ns
ESR, baseline ns ns ns r = -0.24, p = 0.031
ESR, 12 months ns ns r = -0.33, p = 0.004 r = -0.22, p = 0.053
CRP, baseline ns ns ns r = -0.28, p = 0.012
CRP, 12 months ns ns r = -0.28, p = 0.015 r = -0.30, p = 0.008
IL-6, baseline ns ns ns ns
IL-6, 12 months ns r = -0.25, p = 0.037 ns ns
IGFSD, baseline r = 0.36, p = 0.003 ns ns ns
IGFSD, 12 months ns ns ns ns
ΔIGFSD, 0 to 12 months r = -0.31, p = 0.017 ns ns r = -0.25, p = 0.038
BMI = body mass index; CRP = C-reactive protein; 1CTP = C-terminal propeptide of type I collagen; CTX = C-terminal telopeptides crosslaps; 
ESR = erythrocyte sedimentation rate; IGFSD = insulin-like growth factor-1, standard deviation scores; IL-6 = interleukin-6; ns = not significant; 
P1NP = Procollagen type I N-terminal propeptide. Bold p values are statistically significant.Arthritis Research & Therapy    Vol 10 No 6    Engvall et al.
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Anabolic factors
At baseline, IGF-1 was in the normal range, median (interquar-
tile range) 165 (133 to 198) corresponding to IGFSD of 0.15
(-0.5 to 0.7). At 12 months there was a significant increase in
IGF-1 (+43; 18 to 76; p < 0.001) and IGFSD (0.90; 0.30 to
1.50; p < 0.001) in the P-group (corresponding figures for the
NoP-group were +6; -17 to 29; p = 0.27; and 0.20; -0.40 to
0.70; p = 0.051, respectively) and the changes at 0 to 12
months in both variables were significantly greater in the P-
group than in the NoP-group (p < 0.001 for both
comparisons).
Correlations between IGF-1 and bone mineral density 
and bone markers
At baseline, including all patients, IGF-1 correlated positively
with BMD at the lumbar spine and femoral neck (r = 0.20, p =
0.016 and r = 0.17, p = 0.049, respectively). IGFSD at base-
line also correlated positively with baseline BMD at the lumbar
spine, but not at the femoral neck (r = 0.20, p = 0.017 and r =
0.06, p = 0.50, respectively).
Baseline levels of IGF-1 also correlated negatively with both
CTX-1 and 1CTP (r = -0.21, p = 0.012 and r = -0.38, p <
0.001, respectively). IGF-1 at baseline did not correlate with
P1NP. Results of the univariate analyses considering IGFSD
and changes in BMD for both the treatment groups are shown
in Table 3. Also, in the NoP-group a higher IGF-1 at 12 months
correlated with better BMD at the femoral neck after two years
(r = 0.31, p = 0.009) and a higher IGFSD at 12 months was
associated with better BMD at the lumbar spine at two years
(r = 0.26, p = 0.029).
Thus, higher levels of IGF-1 and IGFSD at baseline for all
patients and higher levels of IGF-1 and IGFSD at 12 months
for the NoP-group were associated with better BMD at both
skeletal sites. However, an increase in IGFSD from 0 to 12
months was associated with a loss of bone at the lumbar spine
for the P-group and a loss of bone at the femoral neck for the
NoP-group. In the P-group, a higher IGF-1 at 12 months was
associated with a smaller decrease in 1CTP between 0 to 12
months (r = 0.27, p = 0.042). In the NoP-group, a higher IGF-
1 at 12 months was associated with a more pronounced
decrease in 1CTP between 0 and 12 months (r = -0.25, p =
0.034).
Prediction of change in bone mineral density
In multiple-linear regression analysis we used stepwise for-
ward regression with the variables with p < 0.05 from the uni-
variate analysis, as well as variables known to be important for
osteoporosis: age, gender, BMI and smoking. Results of the
multiple-linear regression analysis are shown in Table 4.
In the lumbar spine higher levels of bone markers and treat-
ment with glucocorticoids were associated with lower BMD.
Impact of gender was different in the two treatment groups; in
the P-group women lost more bone and men lost more bone
in the NoP-group. A higher baseline, IGFSD was associated
with higher BMD in the P-group. Adjusting for age, gender,
smoking or BMI did not change the correlations. Adding men-
opausal status to the models strongly affected them resulting
in an increased adjusted R2 value of 0.31 for the whole group.
At the femoral neck, higher BMI was associated with higher
BMD and a higher level of 1CTP at 12 months was associated
with more bone loss for both groups. Treatment with glucocor-
ticoids had no impact on bone loss at the femoral neck, nor did
gender in either group. Including age, smoking or menopausal
status in the model did not change the correlations.
When looking at gender differences, the most important find-
ing was that in women, glucocorticoid treatment predicted 0
to 24 months change in BMD at lumbar spine (regression
coefficient β = 0.55, standard error of β = 0.10, p < 0.001).
Discussion
In this prospective, open study of early, active RA over two
years the patients who were in the original study were ran-
domised to 7.5 mg prednisolone or no prednisolone when
they started their treatment with DMARD. This treatment could
not prevent bone loss in the spine, in spite of decreased
inflammation and decreased bone resorption. In the P-group,
bone loss was prevented in the femur compared with the NoP-
group where BMD also decreased in the hip.
The decrease in BMD at the lumbar spine was more pro-
nounced in women in the P-group, especially in the postmen-
opausal women. This difference was evident even when
excluding women around the age of menopause, a period with
early menopause-associated trabecular BMD loss. In premen-
opausal women and men, there was no difference in lumbar
spine bone loss between the treatment groups. It thus seems
that menopausal status was a risk factor for bone loss in the
spine in combination with treatment with glucocorticoids. Pre-
vious results concerning the effects of menopausal status in
glucocorticoid-treated RA patients were conflicting [29,30].
The fact that bone loss in the P-group was only evident in the
spine and not in the femur might partly depend on the fact that
trabecular bone, which has a higher bone turnover than corti-
cal bone [31], is more abundant in the spine than in the femo-
ral neck [32]. This makes the spine more vulnerable when the
balance in bone remodelling changes towards decreased
bone formation, a known effect of glucocorticoids [33] also
shown here. Furthermore, postmenopausal osteoporosis also
mainly affects the trabecular bone [34], and the combined
effect of postmenopausal status and glucocorticoid treatment
may increase the vulnerability.
Median levels of the bone markers were not elevated (com-
pared with the reference values) in spite of active disease. ThisAvailable online http://arthritis-research.com/content/10/6/R128
Page 9 of 12
(page number not for citation purposes)
differs from some earlier reports of increased levels in RA
patients with active disease [35,36] but not from all [37]. Here
1CTP was elevated in 38% of the patients at baseline, while
CTX-1 was only elevated in 8%, percentages close to those
reported earlier [37]. 1CTP mirrors the inflammatory mediated
local bone resorption in the arthritic joints, suggested to be
prominent early in disease, more than the systemic bone
resorption such as osteoporosis [38,39] reflected by CTX-1
elevation. The changes in bone resorption markers over time
correlated with reduced inflammation, which has also been
showed by other groups [5,6,19].
The marker of bone formation, P1NP, decreased in the P-
group but remained stable in the NoP-group, which is in
accordance with the known effects of glucocorticoids on
bone. Glucocorticoids thus inhibit bone formation by modify-
ing osteoblastic cell differentiation, number and function [33].
In a study of healthy volunteers, treatment with 10 mg pred-
nisolone resulted in a decreased levels of bone formation
markers and, to a smaller degree, of 1CTP [40].
The bone resorption markers decreased in both groups but
with different patterns. Thus CTX-1 decreased rapidly within
the first three months, which was more pronounced in the P-
group. This quick response is similar to that achieved by inflix-
imab treatment [19] but in contrast to that treatment the values
did not return to pre-treatment levels after 12 months. The
1CTP level decreased more slowly and in the NoP-group was
only significant at 12 months, also in line with infliximab treat-
ment [19]. The different patterns suggest that CTX-1 and
1CTP reflect different resorption processes. 1CTP is prefer-
entially localised in local joints [37] and tumour necrosis factor
blockade inhibits activity of the 1CTP-generating MMPs [41].
The greater reduction of 1CTP found here in the P-group com-
Table 4
Multiple regression analysis with change in BMD from 0 to 24 months at the lumbar spine (L2 to L4) and femoral neck as dependent 
variables. All variables are adjusted for age, gender, BMI and smoking
Beta Std.Err of beta P-level Adj R2 value
Δ BMD L2 to L4, 0 to 24 months All patients
CRP 12 months -0.25 0.09 0.006 14 to 16%
P1NP 12 months -0.26 0.10 0.009 14 to 16%
Glucocorticoid-treatment (1 = yes, 2 = no) 0.21 0.10 0.036 14 to 16%
IGFSD, baseline 0.17 0.09 0.059 14 to 16%
Δ BMD L2 to L4, 0 to 24 months P-group
Gender (1 = woman, 2 = man) 0.31 0.13 0.022 23 to 27%
1CTP, 12 months -0.25 0.12 0.045 23 to 27%
IGFSD, baseline 0.43 0.12 0.001 23 to 27%
Δ BMD L2 to L4, 0 to 24 months NoP-group
P1NP, 12 months -0.37 0.11 0.001 22 to 23%
Gender (1 = woman, 2 = man) -0.29 0.11 0.010 22 to 23%
Δ BMD femoral neck, 0 to 24 months All patients
BMI 0.31 0.08 <0.001 23%
CRP, 12 months -0.20 0.08 0.017 23%
1CTP, 12 months -0.26 0.09 0.006 23%
Δ BMD femoral neck, 0 to 24 months P-group
BMI 0.37 0.14 0.010 17 to 20%
1CTP, 12 months -0.33 0.12 0.012 17 to 20%
Δ BMD femoral neck, 0 to 24 months NoP-group
CRP, 12 months -0.27 0.11 0.022 20 to 23%
BMI 0.35 0.11 0.003 20 to 23%
1CTP, 12 months -0.26 0.13 0.050 20 to 23%
BMD = bone mineral density; BMI = body mass index; CRP = C-reactive protein; 1CTP = C-terminal propeptide of type I collagen; IGFSD = 
insulin-like growth factor-1, standard deviation scores; P1NP = Procollagen type I N-terminal propeptide.Arthritis Research & Therapy    Vol 10 No 6    Engvall et al.
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pared with the NoP-group indicates a more pronounced inhi-
bition of MMPs induced by prednisolone. This inhibition might
not only explain the earlier reported ability of prednisolone to
reduce radiographic damage in the joints of hands and feet in
the RA patients [9], but also the finding that bone resorption
was only inhibited in the P-group in the femur, a juxta-articular
localisation.
In the P-group, CTX-1 seemed to decrease more than P1NP,
similar to what was observed with infliximab treatment [19].
This means that the reduction of P1NP levels in the P-group
was balanced by the decrease in CTX-1. In contrast, 1CTP did
not seem to decrease as much as P1NP indicating that the
reduced bone formation in the P-group was not balanced by
the reduced 1CTP.
At baseline, only levels of P1NP correlated with changes in
BMD of the lumbar spine two years later. Adequate thresholds
for bone markers are lacking and the current data do not
indicate that bone markers at baseline can predict the rate of
bone loss in an individual with sufficient accuracy to be used
in clinical practice [16]. That suppression of bone resorption
is important was, however, shown as levels of bone markers at
12 months, or the change from 0 to 12 months, predicted
bone loss. This was shown for both treatment groups at both
skeletal sites.
Most clinical studies have shown a positive correlation
between IGF-1 and BMD [42]. Like others, we also found a
positive correlation between IGF-1 and BMD at both skeletal
sites at baseline. IGF-1 increased significantly only in the P-
group. This is in line with other groups who have also found an
association between treatment with glucocorticoids and
increased levels of IGF-1 [43-46]. In patients with Cushing's
syndrome, IGF-1 has also been found to be elevated [47]. A
possible explanation for this unexpected increase in IGF-1
could be that glucocorticoids inhibit the production of IGF-1 in
the muscle, followed by a decrease in negative feedback reg-
ulation of liver IGF-1, which would increase serum levels of
IGF-1 [46]. In correlation analyses, there were a negative cor-
relation between changes in IGF-1 and changes in BMD at the
lumbar spine for the P-group and at the femoral neck for the
NoP-group. Treatment with glucocorticoids can be associated
with IGF-1 resistance [43,44,46], similar to insulin resistance,
which may explain the negative correlation in the P-group.
Canalis and Avioli have postulated that reduced IGF-1 synthe-
sis may be responsible for the inhibition of bone formation
caused by steroids [48]. In the present study we did not find
any significant correlation between IGF-1 and markers of bone
formation, although such a correlation was found between
IGF-1 and the bone resorption markers. The lack of significant
correlation between IGF-1 and the bone formation marker may
be because the effects of IGF-1 on bone occur in a paracrine
or autocrine manner [20]. The fact that in the NoP-group we
found a negative correlation between changes in IGF-1 and
changes in BMD at the femoral neck could be due to the fact
that IGF-1 resistance may be secondary to inflammatory activ-
ity, just like the peripheral insulin resistance. Research over the
past decade indicates the ability of pro-inflammatory cytokines
to induce a state of IGF-1 resistance [49].
The primary limitation of this study is that not all patients in the
randomised study of low-dose prednisolone were included in
this mechanistic study. The reason for this was that only
patients with DXA and radiographs at both baseline and two
years were eligible. This implies that although the study was
randomised the number of patients excluded was different
between treatment arms, which must be considered when
interpreting the results. Furthermore the randomised study
was designed to study radiological progression. When
designing studies on bone density great efforts must be
devoted to comparisons of groups with mixed gender, age and
different menopausal status. However, being aware of these
shortcomings, we tried to adjust for these differences in the
analyses. Further, the blood for bone turnover markers was not
obtained in the fasting state, which may have affected some of
the results. Blood samples were usually drawn at the same
time for each individual patient. Another limitation of this study
is that no placebo was used.
Conclusion
The data presented indicate that glucocorticoids counteract
the negative impact of rheumatoid inflammation on bone tis-
sue. In the hip with its bone tissue close to a large joint, BMD
was preserved in the P-group. However, in the spine, a skeletal
site not directly affected by the synovial inflammatory process
in RA, glucocorticoid treatment was associated with a
decrease in BMD. In the light of these data we suggest that
glucocorticoids may protect against the negative effects on
bone primarily caused by the rheumatoid disease, a sugges-
tion supported by the rapid decrease in 1CTP in the P-group.
On the other hand, the systemic inflammatory consequences
on bone could not be prevented because of suppression of
bone synthesis. Bone loss in the spine was more pronounced
in postmenopausal women treated with glucocorticoids. Bone
protection for this group of patients should always be consid-
ered, especially if glucocorticoids are given.
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